3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
28
Lymphoma, Mantle-Cell
14
Lymphoma, Non-Hodgkin
8
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma
5
Leukemia, B-Cell
4
Multiple Myeloma
3
Lymphoma, B-Cell
3
Waldenstrom Macroglobulinemia
2
Recurrence
2
Pancreatic Neoplasms
2
Lymphoma, Follicular
2
Lymphatic Diseases
2
Leukemia, Prolymphocytic
2
Leukemia
2
Squamous Cell Carcinoma of Head and Neck
1
Part1: Advanced B-cell Malignancies
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphoproliferative Disorders
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Hairy Cell
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Heart Failure
1
Glioblastoma
1
DLBCL
1
Interventions
Carboplatin
367
Pemetrexed
308
pembrolizumab
302
Cisplatin
242
Paclitaxel
230
Docetaxel
199
Gemcitabine
130
Nivolumab
121
Erlotinib Hydrochloride
114
Bevacizumab
85
osimertinib
78
atezolizumab
65
durvalumab
58
Cetuximab
57
130-nm albumin-bound paclitaxel
56
Gefitinib
52
Ipilimumab
46
Afatinib
38
Drug Therapy
33
Cyclophosphamide
30
Crizotinib
30
Albumin-Bound Paclitaxel
30
Vinorelbine
28
cemiplimab
26
tislelizumab
25
avelumab
23
icotinib
22
Radiotherapy
22
capmatinib
21
Oxaliplatin
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Non-Small-Cell Lung
×
acalabrutinib
×
Clear all
NCT02448303
2019-09-12
KEYNOTE166
Acerta Pharma BV
Phase 2
Completed
74 enrolled
10 charts